“pet/ct has disappeared. You see the high-intake stoves on the film, they're gone." in recent days, professor zhang sword, director of clinical trial room i, professor zing dongmei of the lymphoma team, and dr. Shenvina have brought the long-awaited good news to aunt tan of lymphoma transfer patients at the university hospital for oncology (pudong hospital): car-t cell immunotherapy is in effect
At the beginning of the year, after aunt teng had accidentally found herself suffering from lymphoma and went to hospital for treatment, the condition was partially controlled; however, despite the rescue treatment, the rest of the stoves were moving rapidly in a short period of time. Auntie teng suffered from rational fractures due to cancer cells and entire bones, and was unable to walk and had to sit in a wheelchair。
The lymphoma treatment team at the oncology hospital assessed that the routine treatment programme was no longer effective for aunt ten. “ten is an incurable lymphoma, and it is difficult to benefit even from programmes such as the use of newer target treatment” zhang sword says, “after a thorough assessment by the multidisciplinary integrated treatment team for lymphoma in my home, you have given aunt teng advice on the next step in treatment, of which the newly listed car-t-cell immunotherapy is an option.”
It is described that the full name of car-t cytology therapy is “t-cell immunotherapy with embedded antigen receptors”. The car refers to embedded antigen receptors whose rationale is to activate the t-lymphocytes of the human body itself. In this therapy, car is loaded on the surface of t-lymphocytes, working in concert with t-cells, which are equivalent to a “gps navigational system” capable of identifying accurately antigens specific to the surface of tumour cells, while t-lymphocytes, as “immunizing forces”, will proactively eliminate these “bad molecules” — that is, using the human own immune system to remove cancer cells and achieve therapeutic effects。
After full knowledge and consideration, the family decided to receive car-t-cell immunotherapy at the university hospital for oncology. Director chu ching fei, center for clinical research, stated that the success of car-t therapy required extremely rigorous overall management, starting with the completion of human t-lymphocytes, assisted by an experienced medical team, before further processing through in vitro build-up, then re-transmitting “gps” t-cells back to the body to complete the critical treatment process。
In early october, auntie teng completed the first phase of the t-cell collection; in november, t-cells successfully returned. With the close attention of the medical team of the clinical trial room i, aunt tent did not suffer a clear adverse reaction after her defeat. “all tests are now back to normal, and all aspects of video science are satisfactory.” qinmei said, “this means that the car-t-cell immunotherapy is working on aunt teng! This is, of course, a follow-up visit one month after the treatment, and future aunt ten needs to further observe the effects of the treatment through continuous follow-up.”
“car-t-cell immunotherapy is a very high level of social concern in recent years.” “car-t-cell immunotherapy is currently used clinically mainly to treat lymphoma patients with relapse and lack of second-line treatment programmes. The use of drugs is subject to a full assessment by a medical institution with extensive experience.”
Zhang sword indicated that, in addition to conducting independent car-t research, the clinical trial room i of the oncology hospital attached to the university of jordan had initiated a number of cytological immunotherapy clinical trials similar to car-t in collaboration with pancreas surgery, oncology gynaecology, head neck surgery and osteoporosis surgery. Cell therapy reaches the field of real tumours, a hot spot and a hard spot for the current international treatment of tumours, and it will make a breakthrough in the future。
